Adam Yaari
About Adam Yaari
Adam Yaari is a co-founder and CEO who has significantly contributed to cancer research through co-authoring several influential papers on topics ranging from drug response prediction to the interpretation of cancer mutations.
Adam Yaari, Co-Founder & CEO
Adam Yaari is recognized as the Co-Founder and CEO of his company. His leadership role emphasizes his significant contribution and active involvement in steering the company's strategies and operations. Details about the company and its specific domain were not provided.
Adam Yaari Publications on Cancer Research
Adam Yaari has co-authored multiple influential papers in the field of cancer research. Notable publications include 'Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells' (November 9, 2020), 'Interpretation of cancer mutations using a multiscale map of protein systems' (October 1, 2021), and 'Biologically informed deep neural network for prostate cancer discovery' (September 22, 2021). His research has contributed to understanding cancer mutations and drug responses through advanced machine learning and deep neural networks.
Adam Yaari's Research on Somatic Mutation Rates
On June 20, 2022, Adam Yaari co-authored 'Genome-wide mapping of somatic mutation rates uncovers drivers of cancer'. This publication sheds light on the genetic mutations associated with cancer through comprehensive genome mapping. The study aims to identify the key mutation drivers, contributing valuable insights to the field of oncology.
Multi-resolution Modeling in Cancer Research by Adam Yaari
Adam Yaari's paper, 'Multi-resolution modeling of a discrete stochastic process identifies causes of cancer', published on May 4, 2021, explores the complex mechanisms behind cancer development using multi-resolution modeling techniques. This work enhances understanding of the stochastic processes that play a crucial role in cancer progression.
Adam Yaari Articles on Cancer Mutations
In 2022, Adam Yaari co-authored two significant articles on cancer mutations. 'New model helps identify mutations that drive cancer' (June 20, 2022) investigates new methodologies for pinpointing cancer-driving mutations. Additionally, 'Digging into the dark matter of the genome to uncover mutations that drive cancer' (November 1, 2022) delves into the lesser understood areas of the genome to highlight impactful mutations. These works collectively push forward the boundaries of cancer genomics.